(Press Enter)
|
Topic |
Code/Metric |
Response/Reference |
|---|---|---|
|
Topic:
Activity Metrics |
Code/Metric:
Number of patients treated: HC-BP-000.A |
Response/Reference:
Not reported |
|
Code/Metric:
Number of drugs (1) in portfolio and (2) in research and development (Phases I-III). |
Response/Reference:
2020 ESG Report: Innovation and Access to Healthcare >> Innovation |
|
|
Topic:
Safety of Clinical Trial Participants |
Code/Metric:
Discussion, by world region, of management process for ensuring quality and patient safety during clinical trials. |
Response/Reference:
2020 ESG Report: Quality, Integrity and Ethics >> Ethical and Safe Products |
|
Code/Metric:
Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in (1) Voluntary Action Indicated (VAI) and (2) Official Action Indicated (OAI). |
Response/Reference: | |
|
Code/Metric:
Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries: HC-BP-210a.3 |
Response/Reference: | |
|
Topic:
Access to Medicines |
Code/Metric:
Description of actions and initiatives to promote access to healthcare products for priority diseases and in priority countries as defined by the Access to Medicine Index. |
Response/Reference:
2020 ESG Report: Innovation and Access to Healthcare >> Access to healthcare in low- and middle-income countries |
|
Code/Metric:
List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP). |
Response/Reference:
Reyataz (atazanavir) |
|
|
Topic:
Affordability and Pricing |
Code/Metric:
Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic product to market for a defined time period. |
Response/Reference: |
|
Code/Metric:
Percentage change in (1) average list price and (2) average net price across US product portfolio compared to previous year. |
Response/Reference:
2020 ESG Report: Innovation and Access to Healthcare >> Access to Healthcare |
|
|
Code/Metric:
Percentage change in (1) list price and (2) net price of product with largest increase compared to previous year. |
Response/Reference:
2020 ESG Report: Innovation and Access to Healthcare >> Access to Healthcare |
|
|
Topic:
Drug Safety |
Code/Metric:
List of products listed in the Food and Drug Administration's (FDA) MedWatch Safety Alerts for Human Medical Products Database. |
Response/Reference:
2020 ESG Report: Quality, Integrity and Ethics >> Ethical and Safe Products |
|
Code/Metric:
Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System. |
Response/Reference:
2020 ESG Report: Quality, Integrity and Ethics >> Ethical and Safe Products |
|
|
Code/Metric:
Number of recalls issued, total units recalled. |
Response/Reference:
2015: 0 |
|
|
Code/Metric:
Total amount of product accepted for take-back, reuse or disposal. |
Response/Reference:
2020 ESG Report: Quality, Integrity and Ethics >> Ethical and Safe Products |
|
|
Code/Metric:
Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type. |
Response/Reference:
2020 ESG Report: Quality, Integrity and Ethics >> Ethical and Safe Products |
|
|
Topic:
Counterfeit Drugs |
Code/Metric:
Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting. |
Response/Reference:
2020 ESG Report: Quality, Integrity and Ethics >> Ethical and Safe Products |
|
Code/Metric:
Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products. |
Response/Reference:
2020 ESG Report: Quality, Integrity and Ethics >> Ethical and Safe Products |
|
|
Code/Metric:
Number of actions that led to raids, seizure, |
Response/Reference:
2020 ESG Report: Quality, Integrity and Ethics >> Ethical and Safe Products |
|
|
Topic:
Ethical Marketing |
Code/Metric:
Total amount of monetary losses as a result of legal proceedings associated with false marketing claims. |
Response/Reference: |
|
Code/Metric:
Description of code of ethics governing promotion |
Response/Reference:
2020 ESG Report: Quality, Integrity and Ethics >> Ethical Business |
|
|
Topic:
Employee Recruitment, Development and Retention |
Code/Metric:
Discussion of talent recruitment and retention |
Response/Reference:
2020 ESG Report: Our People >> Global Diversity and Inclusion |
|
Code/Metric:
(1) Voluntary and (2) involuntary turnover rate for |
Response/Reference:
Not reported |
|
|
Topic:
Supply Chain Management |
Code/Metric:
Percentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third-party audit programs for integrity of supply chain and ingredients. |
Response/Reference:
BMS adheres to the audit principles of the International Pharmaceutical Supply Chain Initiative (PSCI) for 100% or all audited third-party suppliers |
|
Topic:
Business Ethics |
Code/Metric:
Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery. |
Response/Reference: |
|
Code/Metric:
Description of code of ethics governing interactions with healthcare professionals. |
Response/Reference:
2020 ESG Report: Quality, Integrity and Ethics >> Ethical Business |